Trials / Completed
CompletedNCT06518213
Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit
Efficacy and Safety of First-line Antiretroviral Therapy (ART) With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Introduced at the First Clinical Visit: a Real-life Retrospective Single Arm Single Center Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- University Hospital for Infectious Diseases, Croatia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recommended first-line antiretroviral regimen. Croatia has a centralized care for people living with HIV (PLWH) and all persons are seen and treated in a single center, preferably in a same-day initiation model whenever suitable. This retrospective cohort study evaluated antiretroviral therapy (ART) naïve PLWH who initiated BIC/FTC/TAF, in a same-day model. The goal of the study is to assess safety and efficacy of this model by collecting information from the electronic database of the Croatian HIV Reference Centre.
Conditions
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2022-12-31
- Completion
- 2024-03-31
- First posted
- 2024-07-24
- Last updated
- 2024-07-24
Locations
1 site across 1 country: Croatia
Source: ClinicalTrials.gov record NCT06518213. Inclusion in this directory is not an endorsement.